[go: up one dir, main page]

MX2016002051A - Metodos y kits para la subtipificacion molecular de tumores. - Google Patents

Metodos y kits para la subtipificacion molecular de tumores.

Info

Publication number
MX2016002051A
MX2016002051A MX2016002051A MX2016002051A MX2016002051A MX 2016002051 A MX2016002051 A MX 2016002051A MX 2016002051 A MX2016002051 A MX 2016002051A MX 2016002051 A MX2016002051 A MX 2016002051A MX 2016002051 A MX2016002051 A MX 2016002051A
Authority
MX
Mexico
Prior art keywords
kits
tumors
methods
molecular subtyping
cancer patient
Prior art date
Application number
MX2016002051A
Other languages
English (en)
Inventor
Wirtz Ralph
KNEIP Christoph
Original Assignee
Biontech Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Diagnostics Gmbh filed Critical Biontech Diagnostics Gmbh
Publication of MX2016002051A publication Critical patent/MX2016002051A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La presente invención se relaciona a un método in vitro de identificación del subtipo molecular de un tumor en un paciente con cáncer y a un método de estratificación de un paciente con cáncer para el tratamiento de tumor. La presente invención se relaciona además a kits que son útiles para la identificación de un subtipo molecular de un tumor en un paciente con cáncer.
MX2016002051A 2013-08-19 2014-08-19 Metodos y kits para la subtipificacion molecular de tumores. MX2016002051A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2013002487 2013-08-19
PCT/EP2014/067675 WO2015024942A1 (en) 2013-08-19 2014-08-19 Methods and kits for the molecular subtyping of tumors

Publications (1)

Publication Number Publication Date
MX2016002051A true MX2016002051A (es) 2016-08-17

Family

ID=51399644

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016002051A MX2016002051A (es) 2013-08-19 2014-08-19 Metodos y kits para la subtipificacion molecular de tumores.

Country Status (16)

Country Link
US (2) US10808283B2 (es)
JP (1) JP6691864B2 (es)
KR (1) KR102241973B1 (es)
CN (3) CN119242793A (es)
AU (1) AU2014310606B2 (es)
CA (1) CA2921183A1 (es)
DK (1) DK2959021T3 (es)
ES (2) ES2685580T3 (es)
HU (1) HUE040066T2 (es)
IL (1) IL243430B (es)
MX (1) MX2016002051A (es)
NZ (1) NZ716862A (es)
PT (1) PT2959021T (es)
RU (1) RU2690241C2 (es)
SG (1) SG11201601060RA (es)
WO (1) WO2015024942A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2945036T3 (es) 2012-08-16 2023-06-28 Veracyte Sd Inc Pronóstico del cáncer de próstata mediante biomarcadores
KR102241973B1 (ko) 2013-08-19 2021-04-19 비온테크 디아그노스틱스 게엠베하 종양의 분자 서브타이핑을 위한 방법 및 키트
ES2914180T3 (es) * 2015-02-17 2022-06-07 Biontech Diagnostics Gmbh Procedimientos y kits para la subtipificación molecular del cáncer de vejiga
CN108601731A (zh) 2015-12-16 2018-09-28 磨石肿瘤生物技术公司 新抗原的鉴别、制造及使用
JP2019530435A (ja) * 2016-08-15 2019-10-24 オルガノボ インコーポレイテッド 薬物試験のための三次元バイオプリント腫瘍モデル
US11414708B2 (en) 2016-08-24 2022-08-16 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
CN106676000A (zh) * 2016-12-30 2017-05-17 上海星耀医学科技发展有限公司 多腔室基因分析反应装置
US11873532B2 (en) 2017-03-09 2024-01-16 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
CN109385473A (zh) * 2017-08-08 2019-02-26 安徽普元生物科技股份有限公司 HER2基因mRNA核酸检测试剂盒（PCR-荧光探针法）
EP3692014B1 (en) * 2017-10-04 2023-11-22 Battelle Memorial Institute Probe for selectively characterizing enzymes involved in xenobiotic metabolism and method of making and using the same
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
EP3714275A4 (en) 2017-11-22 2021-10-27 Gritstone bio, Inc. REDUCTION OF JUNCTION EPITOPIC PRESENTATION FOR NEOANTIGENS
EP3856933A1 (en) 2018-09-27 2021-08-04 BioNTech Diagnostics GmbH Predictive and prognostic methods in breast cancer
CN109207596A (zh) * 2018-10-07 2019-01-15 浙江数问生物技术有限公司 一种MKi67基因表达检测试剂盒及其检测方法
WO2020094399A1 (en) 2018-11-05 2020-05-14 Biontech Diagnostics Gmbh Predictive methods in breast cancer
CN109913551A (zh) * 2019-03-26 2019-06-21 深圳大学 乳腺癌分型的核酸组合物、乳腺癌分型试剂盒及其使用方法
WO2025101548A2 (en) * 2023-11-08 2025-05-15 Cepheid Her2 low quantification method

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7541141B2 (en) * 1997-02-27 2009-06-02 Wisconsin Alumni Research Foundation Method of using estrogen-related receptor alpha (ERRα) status to determine prognosis, treatment strategy and predisposition to breast cancer, and method of using ERRα as a therapeutic target for the treatment of breast cancer
CN101061480A (zh) * 2004-09-22 2007-10-24 三路影像公司 用来分析和优化用于癌症诊断的标记候选物的方法和计算机程序产品
CN101384903A (zh) * 2006-02-09 2009-03-11 南佛罗里达大学 利用bcl-2水平的增高检测癌肿
PL2297359T4 (pl) 2008-05-30 2014-07-31 Univ North Carolina Chapel Hill Profile ekspresji genów do przewidywania skutków raka piersi
WO2010076322A1 (en) * 2008-12-30 2010-07-08 Siemens Healthcare Diagnostics Inc. Prediction of response to taxane/anthracycline-containing chemotherapy in breast cancer
CN102337327A (zh) * 2010-07-21 2012-02-01 其昌達生物高科技(上海)有限公司 乳腺癌预后28基因阵列检测系统
CN102586410A (zh) * 2011-01-18 2012-07-18 苏州科贝生物技术有限公司 一种定量评估乳腺癌远期复发风险的试剂盒
EP2785873A4 (en) * 2011-11-30 2015-11-11 Univ North Carolina METHOD FOR THE TREATMENT OF BREAST CANCER WITH TAXAN THERAPY
KR102241973B1 (ko) 2013-08-19 2021-04-19 비온테크 디아그노스틱스 게엠베하 종양의 분자 서브타이핑을 위한 방법 및 키트
PL2959021T3 (pl) 2013-08-19 2018-11-30 Biontech Diagnostics Gmbh Sposoby i zestawy do podtypowania molekularnego guzów

Also Published As

Publication number Publication date
AU2014310606B2 (en) 2020-03-05
RU2016109976A3 (es) 2018-04-25
IL243430B (en) 2019-11-28
PT2959021T (pt) 2018-10-10
KR102241973B1 (ko) 2021-04-19
KR20160044033A (ko) 2016-04-22
NZ716862A (en) 2022-05-27
CN105473735A (zh) 2016-04-06
JP2016527910A (ja) 2016-09-15
IL243430A0 (en) 2016-03-31
ES2685580T3 (es) 2018-10-10
US20160201137A1 (en) 2016-07-14
HUE040066T2 (hu) 2019-02-28
CN110468205A (zh) 2019-11-19
HK1218313A1 (en) 2017-02-10
AU2014310606A1 (en) 2016-03-03
RU2016109976A (ru) 2017-09-28
WO2015024942A1 (en) 2015-02-26
ES2951470T3 (es) 2023-10-23
DK2959021T3 (en) 2018-09-10
US20200340065A1 (en) 2020-10-29
SG11201601060RA (en) 2016-03-30
CN119242793A (zh) 2025-01-03
CA2921183A1 (en) 2015-02-26
US10808283B2 (en) 2020-10-20
JP6691864B2 (ja) 2020-05-13
RU2690241C2 (ru) 2019-05-31

Similar Documents

Publication Publication Date Title
MX2016002051A (es) Metodos y kits para la subtipificacion molecular de tumores.
TW201613647A (en) Compounds and compositions for treating HER2 positive tumors
MX2019004193A (es) Combinacion de anticuerpos anti-kir y anticuerpos anti-pd-1 para tratar cancer.
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
MY176706A (en) Biomarkers and methods of treating pd-1 and pd-l1 related conditions
MX2015007185A (es) Uso de eribulina en el tratamiento de cancer de pecho.
TN2015000396A1 (en) Antibody drug conjugates
MX2018008426A (es) Combinaciones anti-egfr para tratar tumores.
MX360141B (es) Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer.
MX2016004678A (es) Composiciones para el tratamiento del cancer.
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
PH12015501997A1 (en) Compositions and methods for diagnosis and treatment of hepatic cancers
GEP201706612B (en) Methods for the treatment of breast cancer
MX2018008427A (es) Combinaciones anti-cd20 para tratar tumores.
MX2023011187A (es) Metodos para tratar el cancer de prostata.
NZ723884A (en) Methods of treating alzheimer’s disease
MY180834A (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
MX2015013021A (es) 5-bromo-indirrubinas.
PL2959021T3 (pl) Sposoby i zestawy do podtypowania molekularnego guzów
PH12016502298A1 (en) Vegfr2/ang2 compounds
PH12018502571A1 (en) Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
EA201990411A1 (ru) Способы лечения рака предстательной железы
EA201800552A1 (ru) Способ и комбинация для лечения солидной опухоли и набор, содержащий комбинацию